

05-01-01

A/Box Seq

TO/03/10
C
S
U
P
D
O

UTILITY PATENT APPLICATION TRANSMITTAL

(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.

DE1253

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

DNA SEQUENCES ENCODING DYSTROPHIN MINIGENES AND METHODS OF USE THEREOF

and invented by:

Xiao XIAO

15564 U.S. pro
09/845416
04/30/01

If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: 60/200,777

Which is a:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____

Which is a:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____

Enclosed are:

Application Elements

1. Filing fee as calculated and transmitted as described below
2. Specification having 32 pages and including the following:
 - a. Descriptive Title of the Invention
 - b. Cross References to Related Applications (if applicable)
 - c. Statement Regarding Federally-sponsored Research/Development (if applicable)
 - d. Reference to Microfiche Appendix (if applicable)
 - e. Background of the Invention
 - f. Brief Summary of the Invention
 - g. Brief Description of the Drawings (if drawings filed)
 - h. Detailed Description
 - i. Claim(s) as Classified Below
 - j. Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
DE1253

Total Pages in this Submission
82

Application Elements (Continued)

3. Drawing(s) (when necessary as prescribed by 35 USC 113)
a. Formal b. Informal Number of Sheets _____ 8
4. Oath or Declaration
a. Newly executed (original or copy) Unexecuted
b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
c. With Power of Attorney Without Power of Attorney
d. DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. Incorporation By Reference (usable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. Computer Program in Microfiche
7. Genetic Sequence Submission (if applicable, all must be included)
 - a. Paper Copy
 - b. Computer Readable Copy
 - c. Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. Assignment Papers (cover sheet & documents)
9. 37 CFR 3.73(b) Statement (when there is an assignee)
10. English Translation Document (if applicable)
11. Information Disclosure Statement/PTO-1449 Copies of IDS Citations
12. Preliminary Amendment
13. Acknowledgment postcard
14. Certificate of Mailing
 First Class Express Mail (Specify Label No.): EL763938209US

**UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.

DE1253

Total Pages in this Submission

82

Accompanying Application Parts (Continued)

15. Certified Copy of Priority Document(s) *(if foreign priority is claimed)*
16. Small Entity Statement(s) - Specify Number of Statements Submitted: independant inventor
17. Additional Enclosures *(please identify below):*

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

18. Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
DE1253

Total Pages in this Submission
82


Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	28	- 20 =	8	x \$9.00	\$72.00
Indep. Claims	3	- 3 =	0	x \$40.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
					BASIC FEE \$355.00
OTHER FEE (specify purpose) _____					\$0.00
					TOTAL FILING FEE \$427.00

A check in the amount of _____ to cover the filing fee is enclosed.
 The Commissioner is hereby authorized to charge and credit Deposit Account No. 01-1944 as described below. A duplicate copy of this sheet is enclosed.
 Charge the amount of \$427.00 as filing fee.
 Credit any overpayment.
 Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
 Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance pursuant to 37 C.F.R. 1.311(b).

Dated: April 30, 2001



Signature

Eugene Lieberstein
Reg. No. 24,645

CC:

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Application of: Xiao XIAO
Ser. No.: to be assigned
Filed: herewith
For: DNA SEQUENCES ENCODING DYSTROPHIN
MINIGENES AND METHODS OF USE THEREOF
Group Art Unit: to be assigned
Examiner: to be assigned

STATEMENT REGARDING FEDERALLY SPONSORED
RESEARCH/DEVELOPMENT

Applications

Hon. Commissioner of Patents
& Trademarks
Washington, DC 20231

April 30, 2001

SIR:

Applicant states that this research was partially funded by a grant from the
National Institute of Health. The funding was provided under **federal grant no.: AR45925**.

Respectfully submitted,



Eugene Lieberstein
Reg. No. 24,645

EL:nlm